Introduction/Background The Japanese guideline for treatment of endometrial cancer (2018 edition) recommends using hormonal therapy in relapsed cases if hormone receptor status (estrogen receptor/progesterone receptor) is positive.

Methodology We administered medroxyprogesterone acetate (MPA), 200 mg or 400 mg/day, as maintenance hormone therapy following chemotherapy in two patients with recurrent endometrial cancer.

Results The first patient with stage IIIC (pT2N1M0) moderately-differentiated endometrioid carcinoma of the uterine corpus underwent initial operation and postoperative chemotherapy (paclitaxel plus carboplatin for six cycles). After 2 years, multiple lung metastases were found. The patient achieved clinical complete response (cCR) after second- (pirarubicin plus carboplatin for six cycles) and third-line (docetaxel plus carboplatin for six cycles) chemotherapies followed by MPA maintenance therapy (200 mg/day) and has been disease-free for over 4 years. The second patient with stage II moderately-differentiated endometrioid carcinoma of the uterine corpus developed multiple lung metastases 29 months after initial operation. Subsequent chemotherapy (paclitaxel plus carboplatin for eight cycles) resulted in cCR. Thereafter, MPA (400 mg/day) was orally administered as maintenance therapy. She has been disease-free for over 2 years. The hormone receptor status in both cases was positive, and no serious adverse events were observed in either patient.

Conclusion MPA maintenance therapy should be considered after chemotherapy to treat recurrent endometrial cancer in cases with positive hormone receptor status.

Disclosure Nothing to disclose.